Carmel Jacobs1,2, Brian Hutton3, Sasha Mazzarello4, Stephanie Smith4, Anil Joy5, Eitan Amir6, Mohammed F K Ibrahim7, Nancy Gregario6, Kelly Daigle4, Lori Eggert4, Mark Clemons4. 1. The Ottawa Hospital Cancer Center and University of Ottawa, Ottawa, ON, Canada. jacobscarmel@hotmail.com. 2. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Box 900, Ottawa, ON, K1H 8L6, Canada. jacobscarmel@hotmail.com. 3. University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada. 4. The Ottawa Hospital Cancer Center and University of Ottawa, Ottawa, ON, Canada. 5. Department of Oncology, Division of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada. 6. Division of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada. 7. Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.
Abstract
PURPOSE: Despite the widespread use of steroid prophylaxis schedules for breast cancer patients receiving docetaxel chemotherapy, questions still exist regarding their optimal use. We surveyed health care providers and patients about their experiences with steroid prophylaxis. METHODS: Two questionnaires were developed and circulated. One was presented to health care providers (chemotherapy nurses, pharmacists and medical oncologists) involved in the treatment of breast cancer and the second to patients who had received docetaxel chemotherapy for early stage breast cancer. RESULTS: The health care providers' questionnaire was completed by 184 of 698 invitees: 92/171 (53.8 %) chemotherapy nurses, 56/284 (19.7 %) pharmacists and 36/243 (14.8 %) medical oncologists (overall response rate 26.4 %). Two steroid schedules were found to be the most commonly used: dexamethasone 8 mg BID for 6 doses, with either 3 (79 %) or 2 (11 %) doses taken before docetaxel administration. Suboptimal adherence to steroid premedication had been experienced by 98 % (177/181) of practitioners. Despite the presence of local treatment protocols in 65 % (119/183) of practitioners' institutions, 10 different strategies were commonly used when steroid premedication was taken incorrectly. The patients' questionnaire was completed by 72/87 (82.3 %) invitees. Respondents reported correctly taking their premedication 99 % (70/71) of the time. Patients felt steroids frequently caused side effects, the most common being sleep disturbance (35/72 = 49 %) and skin toxicity (16/72 = 22 %). CONCLUSION: Suboptimal adherence to steroid premedication prior to docetaxel administration is a common clinical challenge. There appears to be discordance between the practitioner and the patient experience. A single, universally accepted and used protocol for both pre- and post-medication and management when premedication is not taken as prescribed could improve adherence.
PURPOSE: Despite the widespread use of steroid prophylaxis schedules for breast cancerpatients receiving docetaxel chemotherapy, questions still exist regarding their optimal use. We surveyed health care providers and patients about their experiences with steroid prophylaxis. METHODS: Two questionnaires were developed and circulated. One was presented to health care providers (chemotherapy nurses, pharmacists and medical oncologists) involved in the treatment of breast cancer and the second to patients who had received docetaxel chemotherapy for early stage breast cancer. RESULTS: The health care providers' questionnaire was completed by 184 of 698 invitees: 92/171 (53.8 %) chemotherapy nurses, 56/284 (19.7 %) pharmacists and 36/243 (14.8 %) medical oncologists (overall response rate 26.4 %). Two steroid schedules were found to be the most commonly used: dexamethasone 8 mg BID for 6 doses, with either 3 (79 %) or 2 (11 %) doses taken before docetaxel administration. Suboptimal adherence to steroid premedication had been experienced by 98 % (177/181) of practitioners. Despite the presence of local treatment protocols in 65 % (119/183) of practitioners' institutions, 10 different strategies were commonly used when steroid premedication was taken incorrectly. The patients' questionnaire was completed by 72/87 (82.3 %) invitees. Respondents reported correctly taking their premedication 99 % (70/71) of the time. Patients felt steroids frequently caused side effects, the most common being sleep disturbance (35/72 = 49 %) and skin toxicity (16/72 = 22 %). CONCLUSION: Suboptimal adherence to steroid premedication prior to docetaxel administration is a common clinical challenge. There appears to be discordance between the practitioner and the patient experience. A single, universally accepted and used protocol for both pre- and post-medication and management when premedication is not taken as prescribed could improve adherence.
Entities:
Keywords:
Breast cancer; Corticosteroid; Docetaxel; Premedication
Authors: Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: M J Piccart; J Klijn; R Paridaens; M Nooij; L Mauriac; R Coleman; M Bontenbal; A Awada; J Selleslags; A Van Vreckem; M Van Glabbeke Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: Miguel Martín; Miguel A Seguí; Antonio Antón; Amparo Ruiz; Manuel Ramos; Encarna Adrover; Ignacio Aranda; Alvaro Rodríguez-Lescure; Regina Grosse; Lourdes Calvo; Agustí Barnadas; Dolores Isla; Purificación Martinez del Prado; Manuel Ruiz Borrego; Jerzy Zaluski; Angels Arcusa; Montserrat Muñoz; José M López Vega; José R Mel; Blanca Munarriz; Cristina Llorca; Carlos Jara; Emilio Alba; Jesús Florián; Junfang Li; José A López García-Asenjo; Amparo Sáez; María José Rios; Sergio Almenar; Gloria Peiró; Ana Lluch Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: J Stemmler; W Mair; M Stauch; J Papke; G Deutsch; W Abenhardt; B Dorn; C Kentenich; M Malekmohammadi; C Jackisch; S Leinung; O Brudler; U Vehling-Kaiser; J Stamp; V Heinemann Journal: Oncology Date: 2005-03-12 Impact factor: 2.935
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: Lori J Goldstein; Anne O'Neill; Joseph A Sparano; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson Journal: J Clin Oncol Date: 2008-08-04 Impact factor: 44.544
Authors: Ming J Poi; Michael Berger; Maryam Lustberg; Rachel Layman; Charles L Shapiro; Bhuvaneswari Ramaswamy; Ewa Mrozek; Erin Olson; Robert Wesolowski Journal: Support Care Cancer Date: 2013-05-19 Impact factor: 3.603
Authors: Mark Clemons; Demetrios Simos; Marta Sienkiewicz; Terry Ng; Labib Zibdawi; Bassam Basulaiman; Arif Awan; Dean Fergusson; Lisa Vandermeer; Deanna Saunders; Brian Hutton; Eitan Amir Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.603
Authors: R Fernandes; S Mazzarello; A A Joy; G R Pond; J Hilton; M F K Ibrahim; C Canil; M Ong; C Stober; L Vandermeer; B Hutton; M da Costa; S Damaraju; Mark Clemons Journal: Support Care Cancer Date: 2018-03-21 Impact factor: 3.603
Authors: Carmel Jacobs; Mark Clemons; Sasha Mazzarello; Brian Hutton; Anil A Joy; Muriel Brackstone; Orit Freedman; Lisa Vandermeer; Mohammed Ibrahim; Dean Fergusson; John Hilton Journal: Support Care Cancer Date: 2017-01-27 Impact factor: 3.603
Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603
Authors: John Hilton; Lisa Vandermeer; Marta Sienkiewicz; Sasha Mazzarello; Brian Hutton; Carol Stober; Dean Fergusson; Phillip Blanchette; Anil A Joy; A Brianne Bota; Mark Clemons Journal: Support Care Cancer Date: 2018-02-06 Impact factor: 3.603
Authors: Sharon McGee; Mashari AlZahrani; Carol Stober; Terry L Ng; Katherine Cole; Gail Larocque; Arif Awan; Sandeep Sehdev; John Hilton; Lisa Vandermeer; Brian Hutton; Gregory Pond; Deanna Saunders; Mark Clemons Journal: J Bone Oncol Date: 2021-02-19 Impact factor: 4.072
Authors: Mashari Alzahrani; Mark Clemons; Marta Sienkiewicz; Noa Shani Shrem; Sharon F McGee; Lisa Vandermeer; Sandeep Sehdev; Marie France Savard; Arif Awan; Christina Canil; Brian Hutton; Gregory Pond; Deanna Saunders; Terry Ng Journal: Support Care Cancer Date: 2021-05-22 Impact factor: 3.603